Articles by Lana Khoury
Lana Khoury is a part-time 1L at American University Washington College of Law with an interest in Intellectual Property, and specifically Patent Law. She is a junior blogger for the IP Brief and earned her B.S. in Biology from the University of California, Riverside.
The Food and Drug Administration’s recent decision, which reasoned that the drug posed public health and safety concerns, creates serious patent implications with regard to generic drugs.
Judge F. Dennis Saylor ended the three and half year battle between Abbott Laboratories and Janssen Biotech Inc. over two antibody patents, finding that Abbott’s patents were invalid, and therefore, could not be infringed.
DNA legend, James D. Watson, filed an amicus brief in Association of Molecular v. Myriad Genetics, Inc. objecting to Myriad’s attempt to patent a breast cancer gene the company isolated.
A recent report by the Federal Trade Commission reveals in increase in the controversial “pay-for-delay” patent settlements whereby brand-name pharmaceutical companies pay off manufacturers of generic drugs to delay the release of their products.
The U.S. Patent and Trademark Office struggles to determine patent eligibility with limited guidance from the Supreme Court.
The ACLU is attempting to put the constitutionality of gene patents on the Supreme Court docket. The gene patents on two breast cancer genes are argued to limit research and prevent crucial medical care and preventative screening.
